All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually.
All subjects will also be followed by record linkage to Cancer Register and Population Register.
Subject residents in Zhongshan City or Wuzhou City
Subject has no medical record of nasopharyngeal carcinoma
ECOG 0-2
Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
Subject has heavy cardiovascular, liver or kidney disease.
Subject has contraindications to nasopharyngeal fiberoptic endoscopy.
Zhongshan People's Hospital, Guangdong, China
Lead sponsor
Wuzhou Red Cross Hospital
Collaborator
Xiamen University
Collaborator